{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:11Z","timestamp":1787026691515,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze real-world evidence on work productivity and daily activity impairment (WPAI) and health-related quality of life (HRQoL) in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients treated with golimumab in Austria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective, non-interventional, multi-center study conducted in RA, PsA and axSpA patients initiating golimumab between April 2016 and May 2020 in 40 centers in Austria. WPAI, HRQoL (RAQoL, ankylosing spondylitis (AS)QoL and PsAQoL) questionnaires and disease activity (Clinical Disease Activity Index, CDAI, in RA and PsA; Bath Ankylosing Spondylitis Disease Activity Index, BASDAI, in axSpA) were assessed at baseline and months 3, 6, 12, 18, and 24. Association between WPAI and disease activity was tested using linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We enrolled 233 patients (RA,\n                      <jats:italic>n<\/jats:italic>\n                      = 95; axSpA,\n                      <jats:italic>n<\/jats:italic>\n                      = 69; PsA,\n                      <jats:italic>n<\/jats:italic>\n                      = 69), 110 patients were followed up to month 24. Mean age was 50.2 \u00b1 14.2 years; 64% were female. Disease activity decreased from baseline to month 24 (RA: CDAI \u221224.3 \u00b1 13.5; axSpA: BASDAI \u22124.4 \u00b1 2.1, and PsA: CDAI \u221221.7 \u00b1 8.5,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001, each). Total work productivity impairment (TWPI), activity impairment and presenteeism subscores continuously decreased throughout month 24 in all indications: RA (\u221258.3 \u00b1 23%, \u221262.6 \u00b1 23.8% and \u221261.7 \u00b1 23.3%, respectively as compared to baseline;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001, each), axSpA (\u221234.4 \u00b1 38.3%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0117; \u221260.9 \u00b1 25.9%, and \u221243.8 \u00b1 26.6%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2264 0.0001 both) and PsA (\u221235.8 \u00b1 43.7%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0186; \u221252.3 \u00b1 25.4%,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001; and \u221243.3 \u00b1 33.5%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0007, respectively). Absenteeism scores decreased only in RA patients (\u22129.2 \u00b1 24.9%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0234). HRQoL improved between baseline and month 24 (RAQoL: \u221212.6 \u00b1 7.5; ASQoL: \u22128.0 \u00b1 4.3; PsAQoL; \u22128.3 \u00b1 6.4,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001, each). TWPI, presenteeism and activity impairment strongly associated with disease activity throughout the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study confirms the benefit of golimumab on work productivity\/daily activity impairment in Austrian RA, PsA, and axSpA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.881943","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T03:46:17Z","timestamp":1654141577000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Christian","family":"Dejaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Resch-Passini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Totzauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Yazdani-Biuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schwingenschloegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Peichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard W.","family":"Naerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","volume":"13","author":"Schett","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B2","first-page":"S32","article-title":"The impact of rheumatoid arthritis and treatment on patients' lives","volume":"28","author":"Strand","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient Burden of Axial Spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00002281-200403000-00014","article-title":"Employment and work disability in rheumatoid arthritis","volume":"16","author":"Backman","year":"2004","journal-title":"Curr Opin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-020-00932-5","article-title":"Work Disability in Axial Spondyloarthritis","volume":"22","author":"Nikiphorou","year":"2020","journal-title":"Curr Rheumatol Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet."},{"key":"B12","unstructured":"Summary of Product Characteristics2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-eular.3666","article-title":"An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab","volume":"77","author":"Scrivo","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/1756-185X.13526","article-title":"Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort","volume":"22","author":"Claudepierre","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e021082","DOI":"10.1007\/s00296-018-4180-4","article-title":"Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non- interventional GO-NICE study in Germany","volume":"8","author":"Kruger","year":"2018","journal-title":"BMJ Open."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0092","article-title":"Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany","author":"Krueger","year":"2020","journal-title":"J Comp Eff Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/reumatology\/36.8.878","article-title":"The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument","volume":"36","author":"de Jong","year":"1997","journal-title":"Br J Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00296-009-1353-1","article-title":"Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status","volume":"31","author":"Garip","year":"2011","journal-title":"Rheumatol Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","article-title":"Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis","volume":"49","author":"Reilly","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire\u2013general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3899\/jrheum.090242","article-title":"Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","article-title":"The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis","volume":"66","author":"Kimball AB Yu","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/acr.22022","article-title":"Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States","volume":"65","author":"Hone","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B29","unstructured":"WPAI Coding"},{"key":"B30","first-page":"199","article-title":"Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS study","volume":"37","author":"Van den Bosch","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.191117","article-title":"Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data from the US corrona psoriatic arthritis\/spondyloarthritis registry","volume":"48","author":"Mease","year":"2021","journal-title":"J Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12325-017-0477-z","article-title":"Impact of adalimumab on work productivity and activity impairment in japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study","volume":"34","author":"Takeuchi","year":"2017","journal-title":"Adv Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","article-title":"Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis","volume":"36","author":"Nakagawa","year":"2019","journal-title":"Adv Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.berh.2011.10.001","article-title":"Economic consequences and potential benefits","volume":"25","author":"Fautrel","year":"2011","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/rheumatology\/keq323","article-title":"Rheumatology and work","volume":"49","author":"Jones","year":"2010","journal-title":"Rheumatology (Oxford)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.881943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T03:46:26Z","timestamp":1654141586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.881943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":35,"alternative-id":["10.3389\/fmed.2022.881943"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.881943","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"881943"}}